GLP-1 therapies are transforming obesity and chronic disease treatment, yet navigating their complex regulatory landscape remains critical. From the Food and Drug Administration’s ‘Green List’ to state-specific rules, compliance isn’t optional – it’s a strategic advantage.

In a recent webinar, McDermott Will & Schulte’s Health & Life Sciences Group explored strategies for scaling GLP-1 programs, covering topics like innovative care delivery models, direct-to-consumer advertising enforcement, and compliance best practices.

Access the webinar recording and key takeaways here.